

Organocatalytic Michael-aldol cascade: formal [3+2] annulation to construct enantioenriched spirocyclic oxindole derivatives

Shu-Wen Duan, Yang Li, Yi-Yin Liu, You-Quan Zou, De-Qing Shi and Wen-Jing Xiao*

Contents


1. General Information
2. Preparation and Spectral Data of Substrates
 - 2.1 General preparation procedure of 3-ylideneoxindoles.
 - 2.2 Spectral Data of Substrates
3. Detailed optimization of reaction conditions
 - 3.1 Optimization of the protection group on the N atom of the oxindole
 - 3.2 Optimization of the ester group in the oxindole
4. General Procedure and Spectral Data of Products
 - 4.1 General Procedure
 - 4.2 Spectral Data of Products
5. X-Ray structure of **3a**.
6. Copies of NMR, MS and Elemental Analysis Spectra

1. General Information

Unless otherwise noted, materials were purchased from commercial suppliers and used without further purification. All the solvents were treated according to general methods. Flash column chromatography was performed using 200-300 mesh silica gel. ^1H NMR spectra were recorded on 400/600 MHz spectrophotometers. Chemical shifts (δ) are reported in ppm from the solvent resonance as the internal standard (CDCl_3 : 7.26 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, dd = doublet of doublets, m = multiplet), coupling constants (Hz) and integration. ^{13}C NMR spectra were recorded on 100/150 MHz with complete proton decoupling spectrophotometers (CDCl_3 : 77.0 ppm). Mass spectra were measured on a MS spectrometer. Elemental analysis was taken on an elementary analysis instrument. Enantiomeric ratios were determined by chiral HPLC with chiral columns (chiralpak AS-H column, chiralpak AD-H column, chiralpak OJ-H column or chiralcel OD-H column) with hexane and i-PrOH as solvents. Optical rotations were measured with a polarimeter.

2. Preparation and Spectral Data of Substrates

2.1 General preparation procedure of 3-ylideneoxindoles.




To a stirred solution of ethyl 2-(triphenylphosphoranylidene) acetate (22 mmol, 1.1 eq.) in anhydrous THF (50 mL), the N-methylindoline-2, 3-dione^[1] (20 mmol, 1.0 eq.) was added at 0 °C. The mixture was stirred at the same temperature until the reaction was completed monitored by TLC analysis. The crude product was purified by flash chromatography on silica gel (petroleum ether/ ethyl acetate 5:1). Compound **1a** was obtained as a red solid (1.74 g, 87% yield).

The other 3-ylideneoxindoles were prepared according to the above procedure.


Reference: [1] Trost, B. M.; Zhang, Y. *J. Am. Chem. Soc.* **2007**, *129*, 14548.

2.2 Spectral Data of Substrates


(E)-Ethyl 2-(1-methyl-2-oxoindolin-3-ylidene)acetate (1a)

 ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.54 (1 H, d, $J = 7.7\text{Hz}$), 7.36 (1 H, t, $J = 7.7\text{Hz}$), 7.05 (1 H, t, $J = 7.7\text{Hz}$), 6.88 (1 H, s), 6.77 (1 H, d, $J = 7.8\text{Hz}$), 4.32 (2 H, q, $J = 7.1\text{Hz}$), 3.21 (3 H, s), 1.37 (3 H, t, $J = 7.1\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.39, 165.54, 145.85, 137.74, 132.30, 128.62, 122.69, 122.31, 119.72, 108.00, 61.07, 26.12, 14.10. MS: $m/z = 231.14$ ($[\text{M}]^+$).


(E)-Ethyl 2-(1,5-dimethyl-2-oxoindolin-3-ylidene)acetate (1b)

 ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.35 (1H, s), 7.15 (1H, d, $J = 8\text{Hz}$), 6.85 (1H, s), 6.65 (1H, d, $J = 8\text{Hz}$), 4.33 (2H, q, $J = 7.1\text{Hz}$), 3.18 (3H, s), 2.34 (3H, s), 1.38 (3H, t, $J = 7\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.38, 165.63, 143.65, 138.06, 132.65, 132.11, 129.23, 121.89, 119.68, 107.71, 61.02, 26.10, 21.03, 14.10. MS: $m/z = 245.17$ ($[\text{M}]^+$).


(E)-Ethyl 2-(5-methoxy-1-methyl-2-oxoindolin-3-ylidene)acetate (1c)

 ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.23 (1 H, d, $J = 2.4\text{Hz}$), 6.91-6.88 (1 H, m), 6.85 (1 H, s), 6.65 (1 H, d, $J = 8.5\text{Hz}$), 4.32 (2 H, q, $J = 7.1\text{Hz}$), 3.82 (3 H, s), 3.17 (3 H, s), 1.37 (3 H, t, $J = 7.1\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.17, 165.45, 155.64, 139.69, 138.24, 122.40, 120.31, 118.07, 114.41, 108.35, 61.05, 55.73, 26.11, 14.08. MS: $m/z = 261.10$ ($[\text{M}]^+$).


(E)-Ethyl 2-(5-fluoro-1-methyl-2-oxoindolin-3-ylidene)acetate (1d)

 ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.36-8.33 (1H, m), 7.09-7.05 (1H, m), 6.90 (1H, s), 6.71-6.68 (1H, m), 4.33 (2H, q, $J = 7\text{Hz}$), 3.21 (3H, s), 1.38 (3H, t, $J = 7\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.11, 165.26, 160.03, 157.65, 141.97, 137.40, 123.65, 120.62, 120.52, 118.63, 118.39, 116.49, 116.22, 108.40, 108.32, 61.33, 26.25, 14.08. MS: $m/z = 249.04$ ($[\text{M}]^+$).


(E)-Ethyl 2-(5-bromo-1-methyl-2-oxoindolin-3-ylidene)acetate (1e)

 ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.70 (1 H, s), 7.48 (1 H, d, $J = 8.2\text{Hz}$), 6.90 (1 H, s), 6.67 (1 H, d, $J = 8.3\text{Hz}$), 4.34 (2 H, q, $J = 7.1\text{Hz}$), 3.21 (3 H, s), 1.39 (3 H, t, $J = 7.1\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 166.87, 165.22, 144.74, 136.67, 134.81, 131.48, 123.89, 121.28, 115.43, 109.43, 61.43, 26.29, 14.13. MS: $m/z = 310.98$ ($[\text{M}]^+$).


(E)-Ethyl 2-(1-methyl-2-oxo-5-(trifluoromethoxy)indolin-3-ylidene)acetate (1f)

 ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.53 (1 H, s), 7.25 (1 H, d, $J = 8.4\text{Hz}$), 6.95 (1 H, d, $J = 1.6\text{Hz}$), 6.78 (1 H, d, $J = 8.5\text{Hz}$), 4.35 (2 H, q, $J = 7.1\text{Hz}$), 3.23 (3 H, s), 1.38 (3 H, t, $J = 7.1\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.18, 165.20, 144.56, 144.43, 136.86, 125.23, 124.22, 122.55, 121.80, 120.59, 119.25, 108.39, 61.46, 26.30, 14.05. MS: $m/z = 315.03$ ($[\text{M}]^+$).


(E)-Ethyl 2-(6-chloro-1-methyl-2-oxoindolin-3-ylidene)acetate (1g)

 ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.48 (1 H, d, $J = 8.3\text{Hz}$), 7.00-6.98 (1 H, m), 6.85 (1 H, s), 6.75 (1 H, d, $J = 1.6\text{Hz}$), 4.31 (2 H, q, $J = 7.1\text{Hz}$), 3.19 (3 H, s), 1.37 (3 H, t, $J = 7.1\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.35, 165.40, 146.92, 138.23, 136.70, 129.70, 122.65, 122.55, 118.13, 108.74, 61.22, 26.23, 14.09. MS: $m/z = 265.09$ ($[\text{M}]^+$).


(E)-Ethyl 2-(6-bromo-1-methyl-2-oxoindolin-3-ylidene)acetate (1h)

 ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.40 (1 H, d, $J = 8.3\text{Hz}$), 7.17-7.14 (1 H, m), 6.91 (1H, d, $J = 1.4\text{Hz}$), 6.87 (s, 1H), 4.31 (2 H, q, $J = 7.1\text{Hz}$), 3.19 (3 H, s), 1.37 (3 H, t, $J = 7.1\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.18, 165.39, 146.84, 136.76, 129.83, 126.57, 125.54, 122.88, 118.52, 111.55, 61.23, 26.22, 14.08. MS: $m/z = 310.94$ ($[\text{M}]^+$).


(E)-Ethyl 2-(7-fluoro-1-methyl-2-oxoindolin-3-ylidene)acetate (1i)

 ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.36 (1 H, d, $J = 7.7\text{Hz}$), 7.14 – 7.03 (1 H, m), 7.02 – 6.88 (2 H, m), 4.32 (2 H, q, $J = 7.1\text{Hz}$), 3.44 (3 H, s), 1.37 (3 H, t, $J = 7.1\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.04, 165.24, 148.67, 146.26, 136.87, 132.29, 124.54, 123.78, 123.08, 123.01, 122.35, 120.22, 120.03, 61.25, 28.81, 28.75, 14.08. MS: $m/z = 249.11$ ($[\text{M}]^+$).


(E)-Ethyl 2-(1,5,7-trimethyl-2-oxoindolin-3-ylidene)acetate (1j)

 ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.28 (1 H, s), 6.91 (1 H, s), 6.85 (1 H, s), 4.32 (2 H, q, $J = 7.1\text{Hz}$), 3.48 (3 H, s), 2.50 (3 H, s), 2.29 (3 H, s), 1.37 (3 H, t, $J = 7.1\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 168.10, 165.60, 141.19, 137.63, 136.76, 131.84, 126.98, 121.43, 120.33, 119.11, 60.93, 29.54, 20.68, 18.81, 14.09. MS: $m/z = 259.10$ ($[\text{M}]^+$).


(E)-Ethyl 2-(1-benzyl-2-oxoindolin-3-ylidene)acetate (1k)

 ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.57 (1 H, d, *J* = 7.7 Hz), 7.42 – 7.18 (6 H, m), 7.01 (2 H, m), 6.68 (1 H, d, *J* = 7.8 Hz), 4.93 (2 H, s), 4.33 (2 H, q, *J* = 7.1 Hz), 1.37 (3 H, t, *J* = 7.1 Hz). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 167.61, 165.57, 145.01, 137.60, 135.35, 132.29, 128.75, 127.67, 127.16, 122.76, 119.90, 109.08, 61.16, 43.76, 14.14. MS: *m/z* = 307.11 ([M]⁺).


(E)-Ethyl 2-(1-allyl-2-oxoindolin-3-ylidene)acetate (1l)

 ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.56 (1 H, d, *J* = 7.7 Hz), 7.33 (1 H, t, *J* = 7.7 Hz), 7.05 (1 H, t, *J* = 7.7 Hz), 6.92 (1 H, s), 6.78 (1 H, d, *J* = 7.9 Hz), 5.88-5.79 (1 H, m), 5.25 (1 H, d, *J* = 7.4 Hz), 5.21 (1 H, s), 4.41 – 4.29 (4 H, m), 1.37 (3 H, t, *J* = 7.1 Hz). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 167.16, 165.55, 145.08, 137.60, 132.25, 130.97, 128.71, 122.69, 122.52, 119.82, 117.62, 108.93, 61.11, 42.30, 14.12. MS: *m/z* = 257.14 ([M]⁺).


(E)-Ethyl 2-(2-oxoindolin-3-ylidene)acetate (1m)

 ¹H NMR (600 MHz, DMSO) δ (ppm) 10.82 (s, 1H), 8.36 (1H, d, *J* = 7.7 Hz), 7.37 (1H, t, *J* = 7.7 Hz), 7.02 (1H, t, *J* = 7.6 Hz), 6.89 (1H, d, *J* = 7.7 Hz), 6.60 (s, 1H), 4.28 (2H, q, *J* = 7.1 Hz), 1.31 (3H, t, *J* = 7.1 Hz). ¹³C NMR (150 MHz, DMSO) δ 167.79, 165.10, 145.04, 138.26, 133.00, 128.09, 121.87, 120.71, 119.56, 110.33, 60.99, 14.01. MS: *m/z* = 217.0 (M⁺).


(E)-tert-Butyl 2-(1-benzyl-2-oxoindolin-3-ylidene)acetate (1n)

 ¹H NMR (400 MHz, CDCl₃) δ 8.54 (1 H, d, *J* = 7.6 Hz), 7.38 – 7.17 (7 H, m), 7.03 (1 H, t, *J* = 7.6 Hz), 6.93 (1 H, s), 6.68 (1 H, d, *J* = 7.7 Hz), 4.94 (2 H, s), 1.58 (10 H, s). ¹³C NMR (100 MHz, CDCl₃) δ 167.79, 164.86, 144.73, 136.49, 135.38, 131.96, 128.72, 128.54, 127.62, 127.12, 125.07, 122.71, 119.95, 109.01, 81.85, 43.67, 28.02. MS: *m/z* = 335.24 (M⁺).

(E)-Benzyl 2-(1-benzyl-2-oxoindolin-3-ylidene)acetate (1o)

 ¹H NMR (400 MHz, CDCl₃) δ 8.56 (1 H, d, *J* = 7.7 Hz), 7.49 – 7.34 (5 H, m), 7.32 – 7.21 (7 H, m), 7.08 – 6.94 (2 H, m), 6.69 (1 H, d, *J* = 7.8 Hz), 5.32 (2 H, s), 4.93 (2 H, s). ¹³C NMR (100 MHz, CDCl₃) δ 167.46, 165.28, 145.01, 138.07, 135.24, 132.43, 128.83, 128.73, 128.57, 128.36, 128.20, 127.65, 127.12, 122.79, 122.16, 119.76, 109.09, 66.84, 43.71. MS: *m/z* = 369.17 (M⁺).

(E)-Methyl 2-(1-methyl-2-oxoindolin-3-ylidene)acetate (1p)



^1H NMR (400 MHz, CDCl_3) δ 8.56 (1 H, d, $J = 7.7\text{Hz}$), 7.38 (1 H, t, $J = 7.7\text{Hz}$), 7.07 (1 H, t, $J = 7.6\text{Hz}$), 6.91 (1 H, s), 6.80 (1 H, d, $J = 7.8\text{Hz}$), 3.88 (3 H, s), 3.24 (3 H, s). ^{13}C NMR (100 MHz, CDCl_3) δ 167.33, 165.97, 145.84, 138.01, 132.42, 128.62, 122.74, 121.69, 119.61, 108.06, 52.08, 26.13. MS: $m/z = 217.09$ (M^+).

3. Detailed optimization of reaction conditions

3.1 Optimization of the protection group on the N atom of the oxindole.

In order to examine the effect of the protection group on the N atom, we prepared the corresponding substrates according to the general procedure. The results are listed in Table S1.

3.2 Optimization of the ester group in the oxindole.

The corresponding substrates were prepared according to the general procedure. The results are listed in Table S2.

Table S1 Optimization of the protection group on the N atom^a

Entry	product	time	yield ^b	ee ^c	
1	 3a	50 min	90%	80	
2	 3l	60 min	96 %	82	
3 ^d	 3m	5 h	32%	-38	

^a Unless otherwise specified, all reactions were carried out with **1** (0.3 mmol), **2** (0.18 mmol), **V** (10 mol%), MgSO_4 (36 mg) in DCM (1 mL) at 15 °C. ^b Isolated yield. ^c Determined by chiral HPLC analysis. ^d The reaction was conducted with 10 mol% of **VI**.


Table S2 Optimization of the ester group^a

Entry	product	time	yield ^b	ee ^c	
1	 3n	5 h	96%	81	
2	 3o	40 min	92 %	79	
3	 3p	50 min	78%	78	

^a Unless otherwise specified, all reactions were carried out with **1** (0.3 mmol), **2** (0.18 mmol), **V** (10 mol%), MgSO_4 (36 mg) in DCM (1 mL) at 15 °C. ^b Isolated yield. ^c Determined by chiral HPLC analysis.

4. General Procedure and Spectral Data of Products

4.1 General Procedure




A mixture of (*E*)-ethyl 2-(1-methyl-2-oxoindolin-3-ylidene)acetate **1a** (0.5 mmol, 115.6 mg), MgSO₄ (60 mg) and cat. **V** (0.005 mmol, 3.0 mg) in DCM (10 mL) was stirred at 15 °C for 30 min followed by addition of **2** (0.3 mmol, 45.7 mg). The crude product was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate 5:1~3:1) to give the desired product **3a** as a white solid.

4.2 Spectral Data of Products


(2'*S*,3*R*,4'*R*)-Ethyl 4'-hydroxy-1-methyl-2-oxo-4',5'-dihydro-2'*H*-spiro[indoline-3,3'-thiophene]-2'-carboxylate(**3a**)

Prepared according to the general procedure from **1a** (0.5 mmol, 115.6 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat. **V** (0.005 mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 7 h to provide the title compound as a white solid (92% yield, mp:126-128 °C, 84% ee, >19:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.60 (1 H, d, *J* = 7.4Hz), 7.37 (1 H, t, *J* = 7.8Hz), 7.12 (1 H, t, *J* = 7.6Hz), 6.93 (1 H, d, *J* = 7.8Hz), 5.02 (1 H, s), 4.60 (1 H, s), 4.30 (1 H, d, *J* = 3.2Hz), 3.91 – 3.69 (2 H, m), 3.47 (1 H, dd, *J* = 11.7Hz, 3.2Hz), 3.32 (3 H, s), 3.22 (1 H, d, *J* = 11.7Hz), 0.79 (3 H, t, *J* = 7.1Hz). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 176.15, 168.23, 143.25, 129.39, 126.00, 124.71, 123.36, 108.36, 79.68, 61.28, 54.75, 54.71, 38.40, 26.57, 13.42. MS: *m/z* = 307.00 ([*M*]⁺). Anal. calcd for (C₁₅H₁₇NO₄S): C, 58.61; H, 5.57; N, 4.56; S, 10.43. found: C, 58.67; H, 5.30; N, 4.38; S, 10.69. [α]_D²⁰ = 99.17 (C = 1.00, CH₂Cl₂). HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, *t*₁ = 12.35 min, *t*₂ = 13.25 min).




Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	12.317	BV	0.2817	1.23544e4	675.69775	91.9714
2	13.266	VB	0.3046	1078.47693	54.28935	8.0286


(2'R,3S,4'S)-Ethyl 4'-hydroxy-1-methyl-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(ent-3a)




Prepared according to the general procedure from **1a** (0.5 mmol, 115.6 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**VI** (0.005mol, 3.2 mg) in distd. DCM (10 mL) at 15 °C for 12 h to provide the title compound as a white solid (96% yield, -87% ee, >19:1 d.r.). [α]_D¹⁷ = -91.87 (C = 0.99, CH₂Cl₂).




(2'S,3R,4'R)-Ethyl 4'-hydroxy-1,5-dimethyl-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(3b)




Prepared according to the general procedure from **1b** (0.5 mmol, 122.6 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 12 h to provide the title compound as a white solid (96% yield, mp:109-112 °C, 83% ee, 17:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.39 (1 H, s), 7.16 (1 H, d, *J* = 7.9Hz), 6.82 (1 H, d, *J* = 7.9Hz), 5.01 (1 H, s), 4.67 (1 H, s), 4.28 (1 H, d, *J* = 3.1Hz), 3.93 – 3.69 (2 H, m), 3.49 (1 H, d, *J* = 11.6Hz), 3.30 (3 H, s), 3.22 (1 H, d, *J* = 11.7Hz), 2.35 (3 H, s), 0.80 (3 H, t, *J* = 7.1Hz). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 176.06, 168.27, 140.87, 133.02, 129.61, 126.02, 125.41, 108.09, 79.74, 61.37, 61.25, 54.77, 38.45, 26.59, 21.12, 13.44. MS: *m/z* = 321.01 ([M]⁺). Anal. calcd for (C₁₆H₁₉NO₄S): C, 59.79; H, 5.96; N, 4.36; S, 9.98. found: C, 59.88; H, 5.79; N, 4.15; S 10.02. [α]_D²¹ = 70.29 (C = 1.00, CH₂Cl₂). HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, *t*₁ = 10.10 min, *t*₂ = 11.54 min).



(2'S,3R,4'R)-Ethyl 4'-hydroxy-5-methoxy-1-methyl-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(3c)




Prepared according to the general procedure from **1c** (0.5 mmol, 130.6 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 10 h to provide the title compound as a white solid (96% yield, mp:128-130 °C, 84% ee, 13:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.25 (1 H, d, *J* = 2.2Hz), 6.90 – 6.82 (2 H, m), 5.02 (1 H, s), 4.67 (1 H, s), 4.29 (1 H, d, *J* = 3.1Hz), 3.94 – 3.72 (5 H, m), 3.47 (1 H, d, *J* = 11.5Hz), 3.30 (3 H, s), 3.21 (1 H, d, *J* = 11.8Hz), 0.84 (3 H, t, *J* = 7.1Hz) ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.63, 168.11, 156.26, 136.60, 127.27, 112.98, 112.44, 108.56, 79.60, 61.47, 61.20, 55.63, 54.53, 38.11, 26.58, 13.41. MS: *m/z* = 337.01 ([M]⁺). Anal. calcd for (C₁₆H₁₉NO₅S): C, 56.96; H, 5.68; N, 4.15; S, 9.50. found: C, 56.94; H, 5.45; N, 4.02; S, 9.60. [α]_D²⁰ = 60.05 (C = 0.98, CH₂Cl₂). HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, *t*₁ = 15.06 min, *t*₂ = 17.11 min).




Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	15.156	BB	0.3552	1.71589e4	747.48737	91.9521
2	17.232	BB	0.4101	1501.79175	56.32570	8.0479


(2'S,3R,4'R)-Ethyl 5-fluoro-4'-hydroxy-1-methyl-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(3d)



Prepared according to the general procedure from **1d** (0.5 mmol, 124.6 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 4 h to provide the title compound as a white solid (92% yield, mp:146-149 °C, 85% ee, 11:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.40 (1 H, dd, *J* = 8.2Hz, 2.5Hz), 7.11 – 7.06 (1 H, m), 6.86 (1 H, dd, *J* = 8.5Hz, 4.2Hz), 5.03 (1 H, s), 4.54 (1 H, s), 4.30 (1 H, d, *J* = 3.2Hz), 3.96 – 3.75 (2 H, m), 3.47 – 3.39 (1 H, m), 3.31 (3 H, s), 3.24 (1 H, d, *J* = 11.9Hz), 0.88 (3 H, t, *J* = 7.1Hz). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.76, 168.02, 160.49, 158.09, 139.30, 127.65, 127.56, 115.69, 115.45, 113.21, 112.95, 108.89, 108.81, 79.44, 61.44, 54.43, 54.39, 38.11, 26.72, 13.49. MS: *m/z* = 325.01 ([M]⁺). Anal. calcd for (C₁₅H₁₆FNO₄S): C, 55.37; H, 4.96; N, 4.31; S, 9.86. found: C, 55.36; H, 4.76; N, 4.18; S, 9.73. [α]_D²⁰ = 74.86 (C = 1.01, CH₂Cl₂). HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, *t*₁ = 11.45 min, *t*₂ = 13.32 min).




(2'S,3R,4'R)-Ethyl 5-bromo-4'-hydroxy-1-methyl-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(3e)




Prepared according to the general procedure from **1e** (0.5 mmol, 155.1 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 3 h to provide the title compound as a white solid (83% yield, mp:122-124

°C, 83% ee, 4:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.72 (1 H, d, *J* = 2.7Hz), 7.52 (1 H, d, *J* = 8.2Hz), 6.82 (1 H, d, *J* = 8.3Hz), 5.02 (1 H, d, *J* = 5.2Hz), 4.46 (1 H, s), 4.29 (1 H, s), 4.02 – 3.74 (2 H, m), 3.44 (1 H, d, *J* = 11.8Hz), 3.31 (3 H, d, *J* = 2.9Hz), 3.24 (1 H, dd, *J* = 11.8Hz, 4.6Hz), 0.90 (3 H, t, *J* = 7.0Hz). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.61, 168.02, 142.43, 132.23, 128.22, 127.74, 116.06, 109.77, 79.48, 61.56, 61.34, 54.43, 38.32, 26.73, 13.57. MS: *m/z* = 384.88 ([M]⁺). Anal. calcd for (C₁₅H₁₆BrNO₄S): C, 46.64; H, 4.18; N, 3.63; S, 8.30. found: C,46.65; H, 4.28; N, 3.49; S, 8.33. [α]_D¹⁷ = 50.84 (C = 0.98, CH₂Cl₂). HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, *t*₁ = 11.83 min, *t*₂ = 14.64 min).




(2'S,3R,4'R)-ethyl 4'-hydroxy-1-methyl-2-oxo-5-(trifluoromethoxy)-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate (3f)




Prepared according to the general procedure from **1f** (0.5 mmol, 157.6 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 10 h to provide the title compound as a white solid (74% yield,

mp:127-129 °C, 86% ee, 6:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.53 (1 H, s), 7.27 (1 H, d, *J* =

3.9Hz), 6.93 (1 H, d, $J = 8.5$ Hz), 5.03 (1 H, s), 4.44 (1 H, s), 4.31 (1 H, d, $J = 3.2$ Hz), 3.98 – 3.75 (2 H, m), 3.41 (1 H, d, $J = 11.9$ Hz), 3.33 (3 H, s), 3.25 (1 H, d, $J = 11.8$ Hz), 0.88 (3 H, t, $J = 7.1$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 175.89, 168.05, 144.94, 142.10, 127.73, 122.45, 121.58, 118.95, 108.79, 79.42, 61.56, 61.45, 54.31, 38.14, 26.74, 13.51. MS: $m/z = 391.00$ ($[\text{M}]^+$). Anal. calcd for ($\text{C}_{16}\text{H}_{16}\text{F}_3\text{NO}_5\text{S}$): C, 49.10; H, 4.12; N, 3.58; S, 8.19. found: C, 49.06; H, 3.90; N, 3.56; S, 8.46. $[\alpha]_{\text{D}}^{16} = 64.79$ ($C = 1.01$, CH_2Cl_2). HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, $t_1 = 7.26$ min, $t_2 = 9.08$ min).




(2'S,3R,4'R)-Ethyl 6-chloro-4'-hydroxy-1-methyl-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(3g)




Prepared according to the general procedure from **1g** (0.5 mmol, 132.8 mg), **2** (0.3 mmol, 45.7 mg), MgSO_4 (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 4 h to provide the title compound as a white solid (87% yield, mp:136-139


°C, 85% ee, 8:1 d.r.). ^1H NMR (400 MHz, CDCl_3) δ (ppm) 7.52 (1 H, d, $J = 8.0$ Hz), 7.09 (1 H, dd, $J = 8.0$ Hz, 1.6Hz), 6.93 (1 H, d, $J = 1.6$ Hz), 5.01 (1 H, s), 4.43 (1 H, s), 4.27 (1 H, d, $J = 3.2$ Hz), 4.00 – 3.70 (2 H, m), 3.46 – 3.36 (1 H, m), 3.30 (3 H, s), 3.23 (1 H, d, $J = 11.8$ Hz), 0.89 (3 H, t, $J = 7.1$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 176.11, 168.10, 144.55, 135.27, 125.69, 124.51, 123.09, 109.14, 79.51, 61.51, 61.04, 54.48, 38.31, 26.72, 13.58. MS: $m/z = 341.04$ ($[\text{M}]^+$). Anal. calcd for ($\text{C}_{15}\text{H}_{16}\text{ClNO}_4\text{S}$): C, 52.71; H, 4.72; N, 4.10; S, 9.38. found: C, 52.93; H, 4.65; N, 4.07; S, 9.36. $[\alpha]_{\text{D}}^{22} = 93.33$ ($C = 0.99$, CH_2Cl_2). HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, $t_1 = 9.95$ min, $t_2 = 12.88$ min).



(2'S,3R,4'R)-Ethyl 6-bromo-4'-hydroxy-1-methyl-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(3h)




Prepared according to the general procedure from **1h** (0.5 mmol, 155.1 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 5 h to provide the title compound as a white solid (89% yield, mp:146-149 °C, 86% ee, 7:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.47 (1 H, d, *J* = 8.0Hz), 7.25 (1 H, dd, *J* = 8.0Hz, 1.5Hz), 7.08 (1 H, d, *J* = 1.3Hz), 5.01 (1 H, s), 4.42 (1 H, s), 4.27 (1 H, d, *J* = 3.2Hz), 3.96 – 3.76 (2 H, m), 3.40 (1 H, d, *J* = 11.8Hz), 3.30 (3 H, s), 3.23 (1 H, d, *J* = 11.8Hz), 0.89 (3 H, t, *J* = 7.1Hz). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.97, 168.09, 144.63, 126.05, 126.00, 125.07, 123.07, 111.90, 79.46, 61.52, 61.09, 54.42, 38.31, 26.71, 13.58. MS: *m/z* = 384.81 ([M]⁺). Anal. calcd for (C₁₅H₁₆BrNO₄S): C, 46.64; H, 4.18; N, 3.63; S, 8.30. found: C, 46.37; H, 4.04; N, 3.62; S, 8.10. [α]_D²⁵ = 77.59 (C = 0.99, CH₂Cl₂). HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, *t*₁ = 10.30 min, *t*₂ = 13.42 min).




Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	10.234	VB	0.2387	1.09004e4	699.07599	92.8033
2	13.339	BB	0.3204	845.30688	40.78711	7.1967


(2'S,3R,4'R)-Ethyl 7-fluoro-4'-hydroxy-1-methyl-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(3i)




Prepared according to the general procedure from **1i** (0.5 mmol, 124.6 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 10 h to provide the title compound as a white solid (81% yield, mp:116-118 °C, 87% ee, 5:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.41 (1 H, d, *J* = 7.3Hz), 7.16 – 7.00 (2 H, m), 5.02 (1 H, s), 4.51 (1 H, s), 4.30 (1 H, d, *J* = 3.3Hz), 4.00 – 3.72 (2 H, m), 3.53 (3 H, d, *J* = 2.8Hz), 3.49 – 3.40 (1 H, m), 3.23 (1 H, d, *J* = 11.8Hz), 0.88 (3 H, t, *J* = 7.1Hz). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.74, 168.08, 148.89, 146.46, 129.99, 128.98, 124.00, 123.93, 120.52, 117.44, 117.25, 79.66, 61.41, 54.77, 54.74, 38.28, 29.09, 13.49. MS: *m/z* = 325.02 ([M]⁺). Anal. calcd for (C₁₅H₁₆FNO₄S): C, 55.37; H, 4.96; N, 4.31; S, 9.86. found: C, 55.40; H, 4.74; N, 4.31; S, 9.92. [α]_D¹⁶ = 92.82 (C = 1.02, CH₂Cl₂). HPLC (Chiralpak OJ-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, *t*₁ = 8.96 min, *t*₂ = 9.98 min).




(2'S,3R,4'R)-Ethyl 4'-hydroxy-1,5,7-trimethyl-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(3j)



Prepared according to the general procedure from **1j** (0.5 mmol, 129.7 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 10 h to provide the title compound as a white solid (94% yield, mp:145-149 °C, 83% ee, 15:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.25 (1 H, s), 6.89 (1 H, s), 4.99 (1 H, s), 4.75 (1 H, s), 4.23 (1 H, d, *J* = 2.9Hz), 3.97 – 3.70 (2 H, m), 3.57 (3 H, s), 3.48 (1 H, d, *J* = 11.7Hz), 3.20 (1 H, d, *J* = 11.7Hz), 2.55 (3 H, s), 2.29 (3 H, s), 0.83 (3 H, t, *J* = 7.1Hz). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 176.69, 168.23, 138.41, 133.45, 132.66, 126.66, 122.96, 119.50, 79.88, 61.08, 60.68, 54.86, 38.37, 29.88, 20.70, 18.78, 13.45. MS: *m/z* = 335.01 ([M]⁺). Anal. calcd for (C₁₇H₂₁NO₄S): C, 60.87; H, 6.31; N, 4.18; S, 9.56. found: C, 61.07; H, 6.18; N, 4.03; S, 9.85. [α]_D²¹ = 82.82 (C = 0.98, CH₂Cl₂). HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, *t*₁ = 10.54 min, *t*₂ = 11.96 min).




(2'S,3R,4'R)-Ethyl 1-benzyl-4'-hydroxy-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(3k)




Prepared according to the general procedure from **1k** (0.5 mmol, 153.7 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C for 6 h to provide the title compound as a white solid (95% yield, mp:104-107 °C, 86% ee, >19:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.60 (1 H, d, *J* = 7.5Hz), 7.39-7.29 (5 H, m), 7.27-


7.24 (1 H, m), 7.07 (1 H, t, $J = 7.6\text{Hz}$), 6.85 (1 H, d, $J = 7.9\text{Hz}$), 5.08 (1 H, s), 5.00 (2 H, dd, $J = 39.7\text{Hz}$, 15.6Hz), 4.63 (1 H, s), 4.33 (1 H, d, $J = 2.9\text{Hz}$), 3.94 – 3.57 (2 H, m), 3.48 (1 H, d, $J = 11.5\text{Hz}$), 3.24 (1 H, d, $J = 11.7\text{Hz}$), 0.59 (3 H, t, $J = 7.0\text{Hz}$). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 176.35, 168.26, 142.35, 134.99, 129.24, 128.72, 127.86, 127.45, 126.20, 124.77, 123.38, 109.39, 80.16, 61.42, 61.37, 54.61, 44.19, 38.28, 13.21. MS: $m/z = 383.02$ ($[\text{M}]^+$). Anal. calcd for $(\text{C}_{21}\text{H}_{21}\text{NO}_4\text{S})$: C, 65.78; H, 5.52; N, 3.65; S, 8.36. found: C, 65.57; H, 5.37; N, 3.55; S, 8.52. $[\alpha]_D^{21} = 67.91$ ($C = 0.99$, CH_2Cl_2). HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, $t_1 = 16.20$ min, $t_2 = 20.07$ min).




(2'R,3S,4'S)-Ethyl 1-benzyl-4'-hydroxy-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(ent-3k)



Prepared according to the general procedure from **1k** (0.5 mmol, 153.6 mg), **2** (0.3 mmol, 45.7 mg), MgSO_4 (60 mg) and cat.**VI** (0.005mol, 3.2 mg) in distd. DCM (10 mL) at 15 °C for 11 h to provide the title compound as a white solid (94% yield, -90% ee, >19:1 d.r.). $[\alpha]_D^{17} = -71.20$ ($C = 1.01$, CH_2Cl_2).




(2'S,3R,4'R)-Ethyl 1-allyl-4'-hydroxy-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(3l)




Prepared according to the general procedure from **1l** (0.5 mmol, 128.6 mg), **2** (0.3 mmol, 45.7 mg), MgSO_4 (60 mg) and cat.**V** (0.005mol, 3.0 mg) in distd. DCM (10 mL) at 15 °C


for 6 h to provide the title compound as a white solid (94% yield, mp: 90-92 °C, 87% ee, >19:1 d.r.). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.61 (1 H, d, *J* = 7.5Hz), 7.33 (1 H, t, *J* = 7.7Hz), 7.11 (1 H, t, *J* = 7.6Hz), 6.93 (1 H, d, *J* = 7.8Hz), 5.90 – 5.83 (1 H, m), 5.31 (2 H, dd, *J* = 18.1Hz, 13.8Hz), 5.04 (1 H, s), 4.57 (1 H, d, *J* = 1.8Hz), 4.44 (2 H, d, *J* = 2.4Hz), 4.30 (1 H, d, *J* = 3.2Hz), 3.93 – 3.75 (2 H, m), 3.50 – 3.46 (1 H, m), 3.23 (1 H, d, *J* = 11.7Hz), 0.79 (3 H, t, *J* = 7.1Hz). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.94, 168.24, 142.40, 130.49, 129.23, 126.14, 124.73, 123.29, 118.14, 109.25, 79.94, 61.42, 61.24, 54.57, 42.69, 38.29, 13.41. MS: *m/z* = 333.03 ([*M*]⁺). Anal. calcd for (C₁₇H₁₉NO₄S): C, 61.24; H, 5.74; N, 4.20; S, 9.62. found: C, 61.48; H, 5.47; N, 3.94; S, 9.71. [*α*]_D²⁰ = 87.05 (C = 0.99, CH₂Cl₂). HPLC (Chiralpak OD-H column, hexane/2-propanol = 90:10, 1.0 mL/min; 254 nm, 25 °C, *t*₁ = 13.28 min, *t*₂ = 14.60 min).




(2'R,3S,4'S)-Ethyl 1-allyl-4'-hydroxy-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate(ent-3l)




Prepared according to the general procedure from **1l** (0.5 mmol, 128.6 mg), **2** (0.3 mmol, 45.7 mg), MgSO₄ (60 mg) and cat.**VI** (0.005mol, 3.2 mg) in distd. DCM (10 mL) at 15 °C for 11 h to provide the title compound as a white solid (93% yield, -91% ee, >19:1 d.r.). [*α*]_D¹⁸ = -88.61 (C = 1.00, CH₂Cl₂).



ethyl 4'-hydroxy-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate (3m)




white solid (mp: 151-154 °C) ^1H NMR (400 MHz, CDCl_3) δ (ppm) 9.50 (1 H, s), 7.58 (1 H, d, $J = 7.4$ Hz), 7.31 (1 H, t, $J = 7.8$ Hz), 7.09 (1 H, t, $J = 7.5$ Hz), 7.02 (1 H, d, $J = 7.7$ Hz), 5.03 (1 H, s), 4.58 (1 H, s), 4.40 (1 H, s), 3.95-3.78 (2 H, m), 3.60 – 3.42 (1 H, m), 3.24 (1 H, d, $J = 11.7$ Hz), 0.83 (3 H, t, $J = 7.0$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 178.77, 168.57, 140.62, 129.45, 126.58, 125.03, 123.32, 110.44, 79.89, 62.15, 61.71, 54.48, 38.40, 13.39. MS: $m/z = 293.19$ ($[\text{M}]^+$). Anal. calcd for ($\text{C}_{14}\text{H}_{15}\text{NO}_4\text{S}$): C, 57.32; H, 5.15; N, 4.77; S, 10.93. found: C, 57.39; H, 5.01; N, 4.88; S, 10.67. HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, $t_1 = 12.04$ min, $t_2 = 14.29$ min).




Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	12.041	BB	0.3252	3996.53052	190.25113	30.8498
2	14.288	BB	0.3862	8958.27734	356.71005	69.1502

***tert*-butyl 1-benzyl-4'-hydroxy-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate (3n)**




white solid (mp: 91-92 °C) ^1H NMR (400 MHz, CDCl_3) δ (ppm) 7.65 (1 H, d, $J = 7.4$ Hz), 7.36 – 7.25 (7 H, m), 7.09 (1 H, t, $J = 7.6$ Hz), 6.86 (1 H, d, $J = 7.8$ Hz), 5.38 (1 H, d, $J = 15.5$ Hz), 5.03 (1 H, s), 4.65 (1 H, s), 4.58 (1 H, d, $J = 15.5$ Hz), 4.33 (1 H, d, $J = 2.8$ Hz), 3.46 (1 H, dd, $J = 11.5$ Hz, 3.0 Hz), 3.22 (1 H, d, $J = 11.7$ Hz), 1.00 (9 H, s). ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 176.64, 167.30, 142.41, 134.86, 129.27, 128.85, 127.86, 127.15, 126.51, 124.94, 123.41, 109.24, 82.26, 80.29, 61.53, 55.65, 44.04, 38.23, 27.08. MS: $m/z = 411.25$ ($[\text{M}]^+$). Anal. calcd for ($\text{C}_{23}\text{H}_{25}\text{NO}_4\text{S}$): C, 67.13; H, 6.12; N, 3.40; S, 7.79. found: C, 67.10; H, 6.10; N, 3.20; S, 7.77. HPLC (Chiralpak AD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, $t_1 = 14.20$ min, $t_2 = 17.28$ min).




Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	14.173	BB	0.3607	940.96271	40.37455	9.3602
2	17.223	BB	0.4575	9111.87598	309.09109	90.6398

benzyl 1-benzyl-4'-hydroxy-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate (3o)




white solid (mp: 105-107 °C) ^1H NMR (400 MHz, CDCl_3) δ (ppm) 7.58 (1 H, d, $J = 7.4\text{Hz}$), 7.35 – 7.20 (9 H, m), 7.18 (1 H, d, $J = 7.7\text{Hz}$), 7.03 (1 H, t, $J = 7.5\text{Hz}$), 6.89 (2 H, d, $J = 7.1\text{Hz}$), 6.61 (1 H, d, $J = 7.8\text{Hz}$), 5.13 (1 H, s), 4.91 (1 H, d, $J = 15.7\text{Hz}$), 4.74 (2 H, dd, $J = 46.2\text{Hz}$, 12.0Hz), 4.62 (1 H, s), 4.30 (2 H, dd, $J = 9.2\text{Hz}$, 6.3Hz), 3.46 (1 H, d, $J = 11.5\text{Hz}$), 3.23 (1 H, d, $J = 11.7\text{Hz}$). ^{13}C NMR 176.25, 168.23, 142.15, 134.97, 134.57, 129.19, 128.74, 128.13, 127.76, 127.12, 125.87, 124.64, 123.38, 109.66, 80.05, 67.23, 61.29, 54.57, 43.78, 38.25. MS: $m/z = 445.35$ ($[\text{M}]^+$). Anal. calcd for ($\text{C}_{26}\text{H}_{23}\text{NO}_4\text{S}$): C, 70.09; H, 5.20; N, 3.14; S, 7.20. found: C, 70.19; H, 5.14; N, 3.22; S, 7.06. HPLC (Chiralpak OD-H column, hexane/2-propanol = 80:20, 1.0 mL/min; 254 nm, 25 °C, $t_1 = 13.10$ min, $t_2 = 17.22$ min).




Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area *s	Height [mAU]	Area %
1	13.245	VB	0.6214	940.52930		23.34769	10.3469
2	17.258	BB	0.8369	8149.41162		150.18855	89.6531

benzyl 1-benzyl-4'-hydroxy-2-oxo-4',5'-dihydro-2'H-spiro[indoline-3,3'-thiophene]-2'-carboxylate (3p)




white solid (mp: 147-150 °C) ^1H NMR (400 MHz, CDCl_3) δ (ppm) 7.58 (1 H, d, $J = 7.5\text{Hz}$), 7.38 (1 H, t, $J = 7.7\text{Hz}$), 7.12 (1 H, t, $J = 7.6\text{Hz}$), 6.94 (1 H, d, $J = 7.8\text{Hz}$), 5.03 (1 H, s), 4.60 (1 H, s), 4.29 (1 H, d, $J = 2.7\text{Hz}$), 3.49 (1 H, dd, $J = 11.7\text{Hz}$, 3.1Hz), 3.37 (3 H, s), 3.33 (3 H, s), 3.24 (1 H, d, $J = 11.7\text{Hz}$). ^{13}C NMR 176.09, 168.83, 143.22, 129.42, 126.03, 124.70, 123.40, 108.48, 79.48, 61.32, 54.39, 52.48, 38.55, 26.65. MS: $m/z = 293.27$ ($[\text{M}]^+$). Anal. calcd for ($\text{C}_{14}\text{H}_{15}\text{NO}_4\text{S}$): C, 57.32; H, 5.15; N, 4.77; S, 10.93. found: C, 57.52; H, 5.39; N, 4.71; S, 10.68. HPLC (Chiralpak AD-H column, hexane/2-propanol = 90:10, 1.0 mL/min; 266 nm, 25 °C, $t_1 = 23.00$ min, $t_2 = 24.89$ min).





Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area *s	Height [mAU]	Area %
1	22.426	BV	0.4888	1.45538e4		461.44934	89.1677
2	24.219	VB	0.5151	1768.03430		52.90700	10.8323

5. X-Ray structure of 3a (CCDC 861216).





6. Copies of NMR, MS and Elemental Analysis Spectra










1b




















zqy949 cdc13
20110923




























































dsb973.cdc13
20111218




3f
















ds9970.cdc13
20111218



3j

















7. Copies of MS and elemental analysis Spectra




Exact Mass 231.09





DSW1 #307 RT: 1.03 AV: 1 NL: 2.91E6
T: + c Full ms [40.00-350.00]




Exact Mass 245.11



DSW2 #527 RT: 1.73 AV: 1 NL: 1.77E6
T: + c Full ms [40.00-350.00]












DSW5 #555 RT: 1.82 AV: 1 NL: 5.44E5
T: + c Full ms [40.00-350.00]




DSW6 #320 RT: 1.80 AV: 1 NL: 1.42E7
T: + c Full ms [40.00-600.00]












Exact mass 307.12



DSW11 #365 RT: 1.72 AV: 1 SB: 322 0.25-1.38, 1.92-2.26 NL: 2.16E5
T: + c Full ms [40.00-500.00]







Exact mass: 257.11



DSW12 #168 RT: 0.81 AV: 1 SB: 233 0.04-0.52, 1.11-1.70 NL: 7.54E4
T: + c Full ms [40.00-500.00]
















Exact mass: 391.07


DSW975 #254 RT: 1.44 AV: 1 NL: 1.41E5
T: + c Full ms [40.00-600.00]




Exact mass: 341.05

DSW973 #326 RT: 1.84 AV: 1 NL: 3.30E5
T: + c Full ms [40.00-600.00]







DSW974 #347 RT: 1.95 AV: 1 SB: 279 0.35-1.58, 2.32-2.63 NL: 1.93E5
T: + c Full ms [40.00-600.00]



DSW976 #273 RT: 1.55 AV: 1 NL: 6.66E5
T: + c Full ms [40.00-600.00]







Exact Mass: 335.12

3j


DSW978 #412 RT: 1.74 AV: 1 NL: 7.01E5
T: + c Full ms [40.00-450.00]







Exact Mass: 383.12


3k

DSW971 #434 RT: 1.83 AV: 1 NL: 6.73E5
T: + c Full ms [40.00-450.00]













analytic functional testing
VarioEL III CHNS
serial number 11033032

27.12.11





No.	Name	Weight [mg]	Content [%]	Peak Area
53	DSW001	1.2640	N: 4.183 C: 55.36 S: 9.728 H: 4.755	1803 17211 1307 4268
54	DSW002	1.2190	N: 3.557 C: 49.06 S: 8.456 H: 3.902	1472 14685 1086 3202
55	DSW003	1.2220	N: 4.072 C: 52.93 S: 9.363 H: 4.649	1695 15895 1212 3988
56	DSW004	1.1920	N: 3.615 C: 46.37 S: 8.104 H: 4.042	1463 13558 1014 3254
57	DSW005	1.1740	N: 4.312 C: 55.40 S: 9.922 H: 4.736	1725 15985 1235 3885



analytic functional testing
VarioEL III CHNS
serial number 11033032

27.12.11

No.	Name	Weight [mg]	Content [%]	Peak Area
53	DSW001	1.2640	N: 4.183 C: 55.36 S: 9.728 H: 4.755	1803 17211 1307 4268
54	DSW002	1.2190	N: 3.557 C: 49.06 S: 8.456 H: 3.902	1472 14685 1086 3202
55	DSW003	1.2220	N: 4.072 C: 52.93 S: 9.363 H: 4.649	1695 15895 1212 3988
56	DSW004	1.1920	N: 3.615 C: 46.37 S: 8.104 H: 4.042	1463 13558 1014 3254
57	DSW005	1.1740	N: 4.312 C: 55.40 S: 9.922 H: 4.736	1725 15985 1235 3885



VarioEL III CHNS
serial number 11033032

No.	Name	Weight [mg]	Content [%]
124	DSW1005	1.1210	N: 4.882 C: 57.39 S: 10.67 H: 5.012
126	DSW1006	1.2130	N: 3.204 C: 67.10 S: 7.768 H: 6.101
127	DSW1007	1.2270	N: 3.215 C: 70.19 S: 7.059 H: 5.141
128	DSW1008	1.2570	N: 4.710 C: 57.52 S: 10.68 H: 5.389

